Scientific basis of neoadjuvant therapy

Vassiliki Tsikitis, Maureen A. Chung, Blake Cady

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neoadjuvant therapy includes systemic chemotherapy or radiotherapy for cancer before surgery. Neoadjuvant agents may be chemotherapeutic or hormonal agents, biological response modifiers, or future genetic manipulations. Neoadjuvant therapy in breast cancer began with attempts to improve advanced local or regional disease, but it is now used in larger but operable disease and is employed in earlier operable cancers. The goals of neoadjuvant therapy included conversion of inoperable to operable disease but evolved to increase rates of breast conservation. It allows direct observation of chemotherapeutic effects and more sophisticated prognostication based on pathological analysis of response extent. Patients even with advanced or inflammatory breast cancer may have excellent long-term disease-free survival and breast conservation. Expanded research opportunities may arise from the study of cancer features before and after neoadjuvant therapy contrasting responders with nonresponders. Neoadjuvant therapy demonstrates the advantages of comprehensive multidisciplinary contemporary patient management for function preservation and cosmetic appearance without sacrificing survival.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalSeminars in Breast Disease
Volume7
Issue number2
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Breast
Inflammatory Breast Neoplasms
Neoplasms
Immunologic Factors
Cosmetics
Disease-Free Survival
Radiotherapy
Observation
Breast Neoplasms
Drug Therapy
Survival
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Scientific basis of neoadjuvant therapy. / Tsikitis, Vassiliki; Chung, Maureen A.; Cady, Blake.

In: Seminars in Breast Disease, Vol. 7, No. 2, 06.2004, p. 51-57.

Research output: Contribution to journalArticle

Tsikitis, Vassiliki ; Chung, Maureen A. ; Cady, Blake. / Scientific basis of neoadjuvant therapy. In: Seminars in Breast Disease. 2004 ; Vol. 7, No. 2. pp. 51-57.
@article{d924415a97a242f9b576c7931b9dbf02,
title = "Scientific basis of neoadjuvant therapy",
abstract = "Neoadjuvant therapy includes systemic chemotherapy or radiotherapy for cancer before surgery. Neoadjuvant agents may be chemotherapeutic or hormonal agents, biological response modifiers, or future genetic manipulations. Neoadjuvant therapy in breast cancer began with attempts to improve advanced local or regional disease, but it is now used in larger but operable disease and is employed in earlier operable cancers. The goals of neoadjuvant therapy included conversion of inoperable to operable disease but evolved to increase rates of breast conservation. It allows direct observation of chemotherapeutic effects and more sophisticated prognostication based on pathological analysis of response extent. Patients even with advanced or inflammatory breast cancer may have excellent long-term disease-free survival and breast conservation. Expanded research opportunities may arise from the study of cancer features before and after neoadjuvant therapy contrasting responders with nonresponders. Neoadjuvant therapy demonstrates the advantages of comprehensive multidisciplinary contemporary patient management for function preservation and cosmetic appearance without sacrificing survival.",
author = "Vassiliki Tsikitis and Chung, {Maureen A.} and Blake Cady",
year = "2004",
month = "6",
doi = "10.1053/j.sembd.2005.01.002",
language = "English (US)",
volume = "7",
pages = "51--57",
journal = "Seminars in Breast Disease",
issn = "1092-4450",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Scientific basis of neoadjuvant therapy

AU - Tsikitis, Vassiliki

AU - Chung, Maureen A.

AU - Cady, Blake

PY - 2004/6

Y1 - 2004/6

N2 - Neoadjuvant therapy includes systemic chemotherapy or radiotherapy for cancer before surgery. Neoadjuvant agents may be chemotherapeutic or hormonal agents, biological response modifiers, or future genetic manipulations. Neoadjuvant therapy in breast cancer began with attempts to improve advanced local or regional disease, but it is now used in larger but operable disease and is employed in earlier operable cancers. The goals of neoadjuvant therapy included conversion of inoperable to operable disease but evolved to increase rates of breast conservation. It allows direct observation of chemotherapeutic effects and more sophisticated prognostication based on pathological analysis of response extent. Patients even with advanced or inflammatory breast cancer may have excellent long-term disease-free survival and breast conservation. Expanded research opportunities may arise from the study of cancer features before and after neoadjuvant therapy contrasting responders with nonresponders. Neoadjuvant therapy demonstrates the advantages of comprehensive multidisciplinary contemporary patient management for function preservation and cosmetic appearance without sacrificing survival.

AB - Neoadjuvant therapy includes systemic chemotherapy or radiotherapy for cancer before surgery. Neoadjuvant agents may be chemotherapeutic or hormonal agents, biological response modifiers, or future genetic manipulations. Neoadjuvant therapy in breast cancer began with attempts to improve advanced local or regional disease, but it is now used in larger but operable disease and is employed in earlier operable cancers. The goals of neoadjuvant therapy included conversion of inoperable to operable disease but evolved to increase rates of breast conservation. It allows direct observation of chemotherapeutic effects and more sophisticated prognostication based on pathological analysis of response extent. Patients even with advanced or inflammatory breast cancer may have excellent long-term disease-free survival and breast conservation. Expanded research opportunities may arise from the study of cancer features before and after neoadjuvant therapy contrasting responders with nonresponders. Neoadjuvant therapy demonstrates the advantages of comprehensive multidisciplinary contemporary patient management for function preservation and cosmetic appearance without sacrificing survival.

UR - http://www.scopus.com/inward/record.url?scp=31744444367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31744444367&partnerID=8YFLogxK

U2 - 10.1053/j.sembd.2005.01.002

DO - 10.1053/j.sembd.2005.01.002

M3 - Article

VL - 7

SP - 51

EP - 57

JO - Seminars in Breast Disease

JF - Seminars in Breast Disease

SN - 1092-4450

IS - 2

ER -